Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and ...

Completion of the transaction is expected in the fourth quarter of 2026.

Altaris has agreed to acquire Simulations Plus, a Research Triangle Park, North Carolina-based developer of drug development ...

Simulations Plus (SLP) has entered into a definitive agreement to be acquired by affiliates of Altaris for $375 in an all-cash transaction. Under the terms of the agreement, Simulations Plus common ...

Simulations Plus reported a 9% increase in total revenue in Q3 2023, driven by its software segment. However, declining gross margins and rising operational costs could impact future profitability.

Simulations Plus SLP recently announced that the FDA (United States Food and Drug Administration) has renewed its DILIsym software licenses for the seventh year in a row. DILIsym is a modernized ...

Simulations Plus ( (SLP)) has released its Q1 earnings. Here is a breakdown of the information Simulations Plus presented to its investors. Simulations Plus, Inc., a prominent entity in the biopharma ...

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and ...

Simulations Plus, Inc., a Durham-based global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, entered into a definitive agreement to be acquired by ...

Simulations Plus has agreed to be acquired by affiliates of Altaris in a deal worth around $375 million.